Biodistribution of samarium-153-EDTMP in rats treated with docetaxel.
OBJECTIVE
Many patients with metastatic bone disease have to use radiopharmaceuticals associated with chemotherapy to relieve bone pain. The aim of this study was to assess the influence of docetaxel on the biodistribution of samarium-153-EDTMP in bones and other organs of rats.


METHODS
Wistar male rats were randomly allocated into 2 groups of 6 rats each. The DS (docetaxel/samarium) group received docetaxel (15 mg/kg) intraperitoneally in two cycles 11 days apart. The S (samarium/control) group rats were not treated with docetaxel. Nine days after chemotherapy, all the rats were injected with 0.1 ml of samarium-153-EDTMP via orbital plexus (25 microCi). After 2 hours, the animals were killed and samples of the brain, thyroid, lung, heart, stomach, colon, liver, kidney and both femurs were removed. The percentage radioactivity of each sample (% ATI/g) was determined in an automatic gamma-counter (Wizard-1470, Perkin-Elmer, Finland).


RESULTS
On the 9th day after the administration of the 2nd chemotherapy cycle, the rats had a significant weight loss (314.50+/-22.09g) compared (p<0.5) to pre-treatment weight (353.66+/- 22.8). The % ATI/g in the samples of rats treated with samarium-153-EDTMP had a significant reduction in the right femur, left femur, kidney, liver and lungs of animals treated with docetaxel, compared to the control rats.


CONCLUSIONS
The combination of docetaxel and samarium-153-EDTMP was associated with a lower response rate in the biodistribution of the radiopharmaceutical to targeted tissues. Further investigation into the impact of docetaxel on biodistribution of samarium-153-EDTMP would complement the findings of this study.
Villarim Neto
Arthur
A
Postgraduate Program in Health Sciences, Federal University of Rio Grande do Norte (UFRN), Brazil.
Açucena
Maria Kadja Meneses Torres
MK
Pereira
Kércia Regina Santos Gomes
KR
Rêgo
Amália Cínthia Meneses
AC
Azevedo
Italo Medeiros
IM
Bernardo-Filho
Mário
M
Medeiros
Aldo Cunha
AC
D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000556:secondary; D000077143:Docetaxel; D004347:Drug Interactions; D008297:Male; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011471:Prostatic Neoplasms / Q000188:drug therapy; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D043823:Taxoids / Q000494:pharmacology*
D018712:Analgesics, Non-Narcotic; D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D043823:Taxoids; D000077143:Docetaxel; C061972:samarium Sm-153 lexidronam